Norgine B.V.
5 products tracked · names used in filings: Norgine B.V.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 27 Apr 2026🇪🇺 EU approval (EC decision)
Xolremdi (mavorixafor) approved in the EU
Marketing authorisation to Norgine B.V.; Orphan, Exceptional circumstances, Additional monitoring · source
Thu 26 Feb 2026🇪🇺 CHMP positive opinion
Xolremdi (mavorixafor): CHMP positive opinion
Norgine B.V.; Orphan, Exceptional circumstances, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Ifinwil eflornithine | Application withdrawn | |
| 🇪🇺 | Xolremdi mavorixafor | Authorised | 2026-04-27 |
| 🇪🇺 | Agilus dantrolene sodium, hemiheptahydrate | Authorised | 2024-05-29 |
| 🇪🇺 | Pedmarqsi sodium thiosulfate | Authorised | 2023-05-26 |
| 🇪🇺 | Feraccru ferric maltol | Authorised | 2016-02-18 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.